IP Library › Granted Patent US 12,618,063
Granted Patent B2
US 12,618,063 · App. 18/774,194 · Granted May 5, 2026

Pan-genotypic agents against influenza virus and methods of using the same

Inventors: Jeffrey S. Glenn (Stanford, CA); Rachel Hagey Saluti (Stanford, CA); Edward A. Pham (Stanford, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
C12N15/11A61P31/16C12N2310/31C12N2310/322C12N2310/3231C12N2310/531
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,618,063
App. No.
18/774,194
Granted
May 5, 2026
Kind
B2
Abstract

Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.

Claims (20)

1 . A composition comprising: an antiviral oligonucleotide compound or salt thereof, comprising an oligonucleotide sequence 5′ CGACCAAAAGAATTC 3′ (SEQ ID NO:56).

2 . The composition of claim 1 , wherein the oligonucleotide comprises an internucleoside linkage selected from: phosphorothioate, phosphorodithioate, phosphoramidate and thiophosphoramidate linkages.

3 . The composition of claim 2 , wherein the oligonucleotide comprises one or more chiral internucleoside linkages.

4 . The composition of claim 1 , wherein the oligonucleotide comprises one or more 2′-modified nucleotides.

5 . The composition of claim 1 , wherein the oligonucleotide comprises at least 5 deoxyribonucleotide units and is capable of recruiting an RNase.

6 . A composition comprising: an antiviral oligonucleotide compound or salt thereof, comprising an oligonucleotide sequence LNA14: 5′CGACcaaaagaATTC 3′ (SEQ ID NO:81), wherein capitalized letters denote LNA nucleotides and lowercase letters denote DNA nucleotides.

7 . The composition of claim 6 , wherein the oligonucleotide comprises an internucleoside linkage selected from: phosphorothioate, phosphorodithioate, phosphoramidate and thiophosphoramidate linkages.

8 . The composition of claim 7 , wherein the oligonucleotide comprises one or more chiral internucleoside linkages.

9 . A method of treating or preventing a virus infection in a subject, the method comprising:

administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of the composition according to claim 1 .

10 . The method of claim 9 , wherein the subject is at risk of influenza A virus infection and the administering protects the subject against infection for 1 week or more.

11 . The method of claim 9 , wherein the administering comprises weekly, biweekly, or monthly administration of an effective dose of the oligonucleotide compound.

12 . The method of claim 9 , wherein the pharmaceutical composition further comprises an additional active agent selected from a second oligonucleotide active agent and an antiviral drug.

13 . The method of claim 9 , wherein the subject has been diagnosed with or is suspected of having an influenza A virus infection.

14 . A method of treating or preventing a virus infection in a subject, the method comprising:

administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of the composition according to claim 6 .

15 . The method of claim 14 , wherein the subject is at risk of influenza A virus infection and the administering protects the subject against infection for 1 week or more.

16 . The method of claim 14 , wherein the administering comprises weekly, biweekly, or monthly administration of an effective dose of the oligonucleotide compound.

17 . The method of claim 14 , wherein the pharmaceutical composition further comprises an additional active agent selected from a second oligonucleotide active agent and an antiviral drug.

18 . The method of claim 14 , wherein the subject has been diagnosed with or is suspected of having an influenza A virus infection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2024
From: GLENN, JEFFREY S.; SALUTI, RACHEL HAGEY; PHAM, EDWARD A.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 068768/0451 →
Continuity (5)
Continuation 17716497 · Apr 8, 2022
Continuation 16792103 · Feb 14, 2020
Continuation In Part 16081818
Provisional Application 62302548 · Mar 2, 2016
Related Publication 20240425852A1 · Dec 26, 2024
References Cited (67)
US 20040242518A1 · Chen et al. · 2004 [cited by applicant]
US 20060148747A1 · Stein et al. · 2006 [cited by applicant]
US 20070213293A1 · McSwiggen · 2007 [cited by examiner]
US 20090042823A1 · Templin et al. · 2009 [cited by applicant]
US 20100254945A1 · Ge et al. · 2010 [cited by applicant]
US 20120003156A1 · Dang et al. · 2012 [cited by applicant]
US 20140303073A1 · Iversen · 2014 [cited by applicant]
US 20150182005A1 · Pires et al. · 2015 [cited by applicant]
US 20170161062A1 · Banerjee et al. · 2017 [cited by applicant]
JP 2009532392A · 2009 [cited by applicant]
JP 2012506698A · 2012 [cited by applicant]
JP 2013049714A · 2013 [cited by applicant]
JP 2013515504A · 2013 [cited by applicant]
JP 2013532965A · 2013 [cited by applicant]
WO WO1992003454A1 · 1992 [cited by applicant]
WO WO2005013901A2 · 2005 [cited by applicant]
WO WO2006110688A2 · 2006 [cited by applicant]
WO WO2007084359A2 · 2007 [cited by applicant]
WO WO2008049078A1 · 2008 [cited by applicant]
WO WO2011060320A1 · 2011 [cited by applicant]
WO WO2013166264A2 · 2013 [cited by applicant]
WO WO2017151795A1 · 2017 [cited by applicant]
WO WO2019159884A1 · 2019 [cited by applicant]
WO WO2020021291A1 · 2020 [cited by applicant]
WO WO2021188931A1 · 2021 [cited by applicant]
Zhang et al., Downregulation of miR-146a inhibits influenza A virus replication by enhancing the type I interferon response in vitro and in vivo, Biomed Pharmacother, 111:740-750 (Mar. 2019). [cited by applicant]
Abe et al., Antisense therapy of influenza, European Journal of Pharmaceutical Sciences 13(1):61-69 (2001). [cited by applicant]
Akbari et al., Improved DNA Fragment Length Estimation in Capillary Electrophoresis, [cited by applicant]
Brown et al., Inhibition of HIV-1 replication by oligonucleotide analogues directed to the packaging signal and trans-activating response region, Antivir Chem Chemother, 17(1):1-9 (2006). [cited by applicant]
Cordero et al., An RNA Mapping DataBase for Curating RNA Structure Mapping Experiments, [cited by applicant]
Cordero, A Mutate-and-Map Protocol for Inferring Base Pairs in Structured RNA, 22 pages (2013). [cited by applicant]
Darty et al., VARNA: Interactive Drawing and Editing of the RNA Secondary Structure, [cited by applicant]
Deigan et al., Accurate SHAPE-Directed RNA Structure Determination, PNAS 106(1):97-102 (2009). [cited by applicant]
De Rijk et al., RNA Viz 2: An Improved Representation of RNA Secondary Structure, Bioinformatics 19(2):299-300 (2003). [cited by applicant]
Gao et al., The Influenza A Virus PB2, PA, NP, and M Segments Play a Pivotal Role during Genome Packaging, [cited by applicant]
Giannecchini et al., Oligonucleotides Derived from the Packaging Signal at the 5' End of the Viral PB2 Segment Specifically Inhibit Influenza Virus In Vitro, [cited by applicant]
Giannecchini et al., Packaging signals in the 5'-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules, Antiviral Research, 92(1):64-72 (2011). [cited by applicant]
Gog et al., Codon Conservation in the Influenza A Virus Genome Defines RNA Packaging Signals, [cited by applicant]
Hagey et al., Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2, Nature Medicine, 28(9);1944-1955, (2022). [cited by applicant]
Hoffmann et al., A DNA Transfection System for Generation of Influenza A Virus from Eight Plasmids, [cited by applicant]
Integrated DNA Technologies, Designing Antisense Oligonucleotides, 16 pages (2011). [cited by applicant]
Jin et al., Inhibition of highly pathogenic avian H5N1 influenza virus propagation by RNA oligonucleotides targeting the PB2 gene in combination with celecoxib, Gene Med; Apr;13(4):243-9 (2011). [cited by applicant]
Kierzek et al., Contributions of Stacking, Preorganization, and Hydrogen Bonding to the Thermodynamic Stability of Duplexes Between RNA and 2'-O-Methyl RNA with Locked Nucleic Acids, [cited by applicant]
Kim et al., A Robust Peak Detection Method for RNA Structure Inference by High-Throughput Contact Mapping, [cited by applicant]
Kim et al., HiTRACE-Web: An Online Tool for Robust Analysis of High-Throughput Capillary Electrophoresis, [cited by applicant]
Kladwang et al., A Mutate-and-Map Strategy for Inferring Base Pairs in Structured Nucleic Acids: Proof of Concept on a DNAA/RNA Helix, Biochemistry 49(35):7414-7416 (2010). [cited by applicant]
Kladwang et al., A Mutate-and-Map Strategy Accurately Infers the Base Pairs of a 35-Nucleotide Model RNA, RNA 17(3):1-14 (2011). [cited by applicant]
Kladwang et al., A Two-Dimensional Mutate-and-Map Strategy for Non-Coding RNA Structure, [cited by applicant]
Kladwang et al., Standardization of RNA Chemical Mapping Experiments, [cited by applicant]
Liang et al., Mutational Analyses of Packaging Signals in Influenza Virus PA, PB1, and PB2 Genomic RNA Segments, [cited by applicant]
Marsh, Specific Residues of the Influenza A Virus Hemagglutinin Viral RNA Are Important for Efficient Packaging into Budding Virions, [cited by applicant]
Marsh, Highly Conserved Regions of Influenza A Virus Polymerase Gene Segments Are Critical for Efficient Viral RNA Packaging, [cited by applicant]
Mathews et al., Incorporating Chemical Modification Constraints into a Dynamic Programming Algorithm for Prediction of RNA Secondary Structure, [cited by applicant]
Mortimer et al., A Fast Acting Reagent for Accurate Analysis of RNA Secondary and Tertiary Structure by SHAPE Chemistry, [cited by applicant]
Mortimer et al., Time-Resolved RNA SHAPE Chemistry: Quantitative RNA Structure Analysis in One Second Snapshots and at Single Nucleotide Resolution, [cited by applicant]
Moss et al., Identification of Potential Conserved RNA Secondary Structure Throughout Influenza A Coding Regions, [cited by applicant]
Muramoto et al., Hierarchy Among Viral RNA (vRNA) Segments in Their Role in vRNA Incorporation into Influenza A Virions, [cited by applicant]
Pang, Simplified RNA Secondary Structure Mapping by Automation of SHAPE Data Analysis, Nucleic Acids Research 39(22):1-11 (2011). [cited by applicant]
Pang, Structural Map of a MicroRNA-122:Hepatitis C Virus Complex, [cited by applicant]
Priore, Influenza A Virus Coding Regions Exhibit Host-Specific Global Ordered RNA Structure, [cited by applicant]
Szretter et al., Influenza: Propagation, Quantification, and Storage, [cited by applicant]
Takahashi et al., Inhibition of influenza virus infection by targeting genome conserved region with non-natural nucleic acid, Nucleic Acids Symp Ser (Oxf).,(53):285-6 (2009). [cited by applicant]
Tian et al., High-Throughput Mutate-Map-Rescue Evaluates SHAPE-Directed RNA Structure and Uncovers Excited States, Cold Spring Harbor Laboratory Press 20:1815-1826 (2014). [cited by applicant]
Vester et al., LNA (Locked Nucleic Acid): High-Affinity Targeting of Complementary RNA and DNA, [cited by applicant]
Wilkinson et al., Selective 2'-Hydroxyyl Acylation Analyzed by Primer Extension (SHAPE): Quantitative RNA Structure Analysis at Single Nucleotide Resolution, [cited by applicant]
Yoon et al., HiTRACE: High-Throughput Robust Analysis for Capillary Electrophoresis, [cited by applicant]
Lebedeva et al., Phosphorothioate oligodeoxynucleotides as inhibitors of gene expression: antisense and non-antisense effects, Applications of antisense therapies to restenosis, p. 101, 1999: ABSTRACT only. [cited by applicant]